Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling studyPrimary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profileClinically different efficacy profile observed relative to XOLAIR® (omalizumab) highlights potential for a fundamental mechanism-based biological differenceCue Biopharma to host conference